Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside.
暂无分享,去创建一个
[1] D. V. Slyke,et al. Quantitative clinical chemistry , 1931 .
[2] C. Muller. ANGINA PECTORIS IN HEREDITARY XANTHOMATOSIS , 1939 .
[3] C. Anfinsen. On the Role of Lipemia Clearing Factor in Lipid Transport , 1954 .
[4] R. Havel,et al. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.
[5] P. Wood,et al. Dietary regulation of cholesterol metabolism. , 1966, Lancet.
[6] R. Lees,et al. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. , 1967, The New England journal of medicine.
[7] E. Buskirk. The National Diet-Heart Study Final Report. , 1969, Circulation.
[8] J. Oncley,et al. Lipoproteins--a current perspective of methods and concepts. , 1969, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Larosa,et al. A specific apoprotein activator for lipoprotein lipase. , 1970, Biochemical and biophysical research communications.
[10] Ancel Keys. Coronary heart disease in seven countries. , 1971, The Medical journal of Australia.
[11] A. Gotto,et al. Studies on the protein defect in Tangier disease. Isolation and characterization of an abnormal high density lipoprotein. , 1972, The Journal of clinical investigation.
[12] R. Levy,et al. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. , 1972, The Journal of clinical investigation.
[13] A. Motulsky,et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.
[14] R. Ross,et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Gotto,et al. A molecular theory of lipid—protein interactions in the plasma lipoproteins , 1974, FEBS letters.
[16] R. Ross,et al. The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.
[17] D. Grafnetter,et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.
[18] M. Brown,et al. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. , 1980, Journal of supramolecular structure.
[19] Jeremy N. Morris,et al. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. , 1980 .
[20] D. Steinberg,et al. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Steinberg. Lipoproteins and atherosclerosis. A look back and a look ahead. , 1983, Arteriosclerosis.
[22] W. Castelli,et al. Epidemiology of coronary heart disease: the Framingham study. , 1984, The American journal of medicine.
[23] M J Davies,et al. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.
[24] S. Kelsey,et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. , 1984, Circulation.
[25] L. Wilkins. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. , 1985, Nutrition reviews.
[26] R. Mahley,et al. Lipoproteins of Special Significance in Atherosclerosis , 1985 .
[27] J. Hupp. Lowering Blood Cholesterol to Prevent Heart Disease , 1985, International Journal of Technology Assessment in Health Care.
[28] D. Steinberg,et al. A Novel Mechanism by which High Density Lipoprotein Selectively Delivers Cholesterol Esters to the Liver , 1986 .
[29] R. Ross. The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.
[30] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[31] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[32] W. A. Bradley,et al. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100 , 1986, Nature.
[33] T. Parker,et al. Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. , 1987, The Journal of clinical investigation.
[34] Daniel Steinberg,et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.
[35] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[36] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[37] M J Malloy,et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.
[38] S. Azen,et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. , 1991, Circulation.
[39] H. Esterbauer,et al. Role of vitamin E in preventing the oxidation of low-density lipoprotein. , 1991, The American journal of clinical nutrition.
[40] B. Lewis,et al. Effects on Coronary Artery Disease of Lipid-Lowering Diet, or Diet Plus Cholestyramine, in the St. Thomasʼ Artherosclerosis Regression Study (STARS) , 1992 .
[41] S. Hulley,et al. Health policy on blood cholesterol. Time to change directions. , 1992, Circulation.
[42] G. Watts,et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.
[43] A. Endo,et al. The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.
[44] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[45] J. Fruchart,et al. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. , 1992, Clinical chemistry.
[46] M. Sanmarco,et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.
[47] Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.
[48] D. Albanes,et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.
[49] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[50] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[51] J. Breslow,et al. Apolipoprotein E and the apolipoprotein E-deficient mouse. , 1995, Annual review of nutrition.
[52] G. Assmann,et al. A unique genetic and biochemical presentation of fish-eye disease. , 1995, The Journal of clinical investigation.
[53] J. Berliner,et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.
[54] D. Kromhout. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.
[55] R. Krauss,et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.
[56] F. Kelly,et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.
[57] A. Tall,et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.
[58] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[59] M. Brown,et al. A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .
[60] J. Strong,et al. The PDAY Study: Natural History, Risk Factors, and Pathobiology , 1997, Annals of the New York Academy of Sciences.
[61] The role of antioxidants in preventive cardiology. , 1997, Current opinion in cardiology.
[62] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[63] M. Moskowitz,et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[64] D. Steinberg. Oxidative Modification of LDL and Atherogenesis , 1998 .
[65] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[66] P. McBride,et al. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. , 1998, Archives of internal medicine.
[67] The cholesterol myth. , 2000 .